Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer
18F-Choline (FCH) uptake parameters are strong indicators of aggressive disease in prostate cancer. Functional parameters derived by magnetic resonance imaging (MRI) are also correlated to aggressive disease. The aim of this work was to evaluate the relationship between metabolic parameters derived by FCH PET/CT and functional parameters derived by MRI.
Materials and methods
Fourteen patients with proven prostate cancer who underwent FCH PET/CT and multiparametric MRI were enrolled. FCH PET/CT consisted in a dual phase: early pelvic list-mode acquisition and late whole-body acquisition. FCH PET/CT and multiparametric MRI examinations were registered and tumoral volume-of-interest were drawn on the largest lesion visualized on the apparent diffusion coefficient (ADC) map and projected onto the different multiparametric MR images and FCH PET/CT images. Concerning the FCH uptake, kinetic parameters were extracted with the best model selected using the Akaike information criterion between the one- and two-tissue compartment models with an imaging-derived plasma input function. Other FCH uptake parameters (early SUVmean and late SUVmean) were extracted. Concerning functional parameters derived by MRI scan, cell density (ADC from diffusion weighting imaging) and vessel permeability (Ktrans and Ve using the Tofts pharmakinetic model from dynamic contrast-enhanced imaging) parameters were extracted. Spearman’s correlation coefficients were calculated to compare parameters.
The one-tissue compartment model for kinetic analysis of PET images was selected. Concerning correlation analysis between PET parameters, K1 was highly correlated with early SUVmean (r = 0.83, p < 0.001) and moderately correlated with late SUVmean (r = 0.66, p = 0.010) and early SUVmean was highly correlated with late SUVmean (r = 0.90, p < 0.001). No significant correlation was found between functional MRI parameters. Concerning correlation analysis between PET and functional MRI parameters, K1 (from FCH PET/CT imaging) was moderately correlated with Ktrans (from perfusion MR imaging) (r = 0.55, p = 0.041).
No significant correlation was found between FCH PET/CT and multiparametric MRI metrics except FCH influx which is moderately linked to the vessel permeability in prostate cancer.
Keywords18F-Choline Positron emission tomography Prostate cancer Kinetic analysis Multiparametric MRI
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
For this type of study (retrospective), the local ethics committee waived the requirement for informed consent.
- 5.Peng Y, Jiang Y, Yang C, Brown JB, Antic T, Sethi I, et al. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score—a computer-aided diagnosis development study. Radiology. 2013;267(3):787–96.CrossRefGoogle Scholar
- 10.Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, et al. 18F-Choline PET/MRI: the additional value of PET for MRI-guided transrectal prostate biopsies. J Nucl Med Off Publ Soc Nucl Med. 2016;57(7):1065–70.Google Scholar
- 12.DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med Off Publ Soc Nucl Med. 2001;42(12):1805–14.Google Scholar
- 13.DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med Off Publ Soc Nucl Med. 2002;43(1):92–6.Google Scholar
- 17.Chondrogiannis S, Marzola MC, Grassetto G, Maffione AM, Rampin L, Veronese E, et al. New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization. Biomed Res Int. 2014;2014:215650.PubMedPubMedCentralGoogle Scholar
- 21.Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med Off Publ Soc Nucl Med. 2008;49(Suppl 2):43S–63S.Google Scholar
- 25.Heusch P, Buchbender C, Kohler J, Nensa F, Beiderwellen K, Kuhl H, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen der Nuklearmedizin. 2013;185(11):1056–62.CrossRefGoogle Scholar
- 26.Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med Off Publ Soc Nucl Med. 2013;54(7):1053–9.Google Scholar
- 27.Vadi SK, Singh B, Basher RK, Watts A, Sood AK, Lal A, et al. 18F-fluorocholine PET/CT complementing the role of dynamic contrast-enhanced MRI for providing comprehensive diagnostic workup in prostate cancer patients with suspected relapse following radical prostatectomy. Clin Nucl Med. 2017;42(8):e355-e36.Google Scholar
- 29.Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, van Moorselaar RJ, Windhorst AD, Schwarte LA, et al. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2015;56(3):365–71.Google Scholar